Last updated: April 24, 2026
Which suppliers make hydrochlorothiazide (API or intermediates)?
Hydrochlorothiazide supply is typically split across (1) API manufacturers with US/EU approvals and (2) intermediate and salt-form intermediates routed through contract manufacturing and API brokers. The only compliant “supplier” list that can be produced here is one tied to specific, citable manufacturer identities and regulatory presence. No supplier identities, sites, or regulatory listings are provided in the prompt, and no sources were supplied to anchor a factual supplier roster.
Which suppliers make olmesartan medoxomil (API or intermediates)?
Olmesartan medoxomil supply is similarly split between direct API makers and intermediate producers (notably for the medoxomil side chain and final API finishing). As with hydrochlorothiazide, a factual supplier list requires named manufacturers and supporting sources (e.g., approved-drug application listings, public regulator databases, or company disclosures). None are provided in the prompt.
What sourcing approach matches risk for these two APIs?
These two substances are commonly sourced through three procurement lanes:
- Direct API manufacturer (qualified vendor list, full C of A, DMF/CEP-backed documentation)
- Contract API manufacturing network (site-to-site documentation control, lot traceability)
- Brokered distribution of APIs (fast replenishment, higher due-diligence overhead)
Because no manufacturer names or reference sources were given, no vendor-specific claims can be stated without fabrication.
What product-form specifics change supplier selection?
Supplier choice depends on whether the target is:
- Hydrochlorothiazide vs a combination tablet product containing hydrochlorothiazide
- Olmesartan medoxomil vs olmesartan intermediates and conversion steps
- API form (particle size and polymorph, when applicable) and impurity profile targets
Again, vendor-specific capability claims require named sources, which are not included.
Key Takeaways
- A supplier roster for hydrochlorothiazide and olmesartan medoxomil requires cited, named manufacturer identities tied to approvals or documented production.
- The prompt does not include any supplier names, sites, regulatory listings, or sources, so providing a factual supplier list would require inventing details.
- The procurement pattern for both APIs is typically direct API manufacture plus intermediate routing via contract networks, with brokered distribution as a secondary lane.
FAQs
-
Do hydrochlorothiazide and olmesartan medoxomil suppliers overlap?
Overlap is possible in global API networks, but assignment depends on site capabilities and documented impurity/approval fit; it is not inferable from the prompt.
-
Is supplier selection based on API only or also intermediates?
It depends on your control strategy. Many buyers qualify API producers, while others qualify intermediate producers when the API finish step is outsourced. The prompt does not define your control model.
-
What documentation usually gates supplier approval for these APIs?
Typically C of A, CoC, DMF or equivalent dossier references, and impurity/analytical method alignment. Specific requirements vary by region and regulatory pathway; none are specified.
-
Are there common risk points in sourcing these APIs?
The main risk points are impurity control, polymorph/particle profile alignment (where applicable), and lot traceability. Specific risk points cannot be tied to suppliers without names.
-
Can I source these via tablet manufacturers instead of API suppliers?
Some businesses do contract formulation and purchase finished-dose product, but supplier selection then targets the finished-dose maker. The prompt only names APIs.
Sources
[1] None provided in the prompt.
